Immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants
The present invention provides for novel immunological and vaccine formulations comprising a newly applied non-crosslinked polyacrylic acid polymer adjuvant. The adjuvants may be combined with a wide variety of immunogens to produce vaccines that are safe and effective when administered to a wide range of target animals. The immunogens may include, but are not limited to: inactivated pathogens, attenuated pathogens, subunits, recombinant expression vectors, plasmids or combinations thereof. The animals may include, but are not limited to: humans, murine, canines, felines, equines, porcines, ovines, caprines and bovines.
1. A vaccine adjuvant comprising a 20-80 kDa cut-off diafiltered pharmaceutically acceptable salt of a linear or branched polyacrylic acid polymer, wherein the polyacrylic acid polymer salt has a weight average molecular weight Mw in the range of 350 to 650 kDa; and a polydispersity index below or equal to 4; wherein the polyacrylic acid polymer salt comprises less than 0.005% w/w of oxidizing agents, based on the total dry weight of the polyacrylic acid polymer salt, and wherein the polyacrylic acid polymer salt is exclusively composed of acrylic acid units that are a salt of acrylic acid or is exclusively composed of acrylic acid units that are the free acid form of acrylic acid and of acrylic acid units that are a salt of acrylic acid.
2. The vaccine adjuvant of claim 1 , wherein the polyacrylic acid polymer salt has a polydispersity index below or equal to 2.5; wherein the polyacrylic acid polymer salt has a weight average molecular weight Mw in the range of 380 to 620 kDa and a polydispersity index below or equal to 4; or has a weight average molecular weight Mw in the range of 400 to 600 kDa and a polydispersity index below or equal to 4; or has a weight average molecular weight Mw in the range of 380 to 620 kDa and a polydispersity index below or equal to 2.5; or has a weight average molecular weight Mw in the range of 400 to 600 kDa and a polydispersity index below or equal to 2.
3. The vaccine adjuvant of claim 1 , wherein the polyacrylic acid polymer salt has a Mark Houwink slope higher or equal to 0.7.
4. The vaccine adjuvant of claim 1 , formulated in a buffered aqueous solution selected from a phosphate, TRIS, Hepes, histidine, or citrate buffer.
5. The vaccine adjuvant of claim 1 , which is sterilized.
6. The vaccine adjuvant of claim 1 , wherein the polyacrylic acid polymer salt is capable of enhancing the Th1 immune response obtained with a vaccine composition.
7. A vaccine composition comprising at least one vaccine agent and the vaccine adjuvant of claim 1 .
8. The vaccine composition of claim 7 , comprising per dose, from about 0.1 to about 8 mg of the vaccine adjuvant, or from about 0.1 to about 4 mg, or from about 0.1 to 2 mg.
9. The vaccine composition of claim 7 , wherein the at least one vaccine agent is an antigen or a vector capable of in vivo expression of an antigen; and/or wherein the antigen is a bacterial antigen of Clostridium tetani, Clostridium diphtheriae, Bordetella pertussis, Haemophilus influenzae type B, Streptococcus pneumoniae, Neisseria meningitidis, Shigella sp, Salmonella typhi, Staphylococcus aureus, Staphylococcus epidermidis, Mycobacterium tuberculosis, Chlamydia trachomatis or pneumoniae or Streptococcus sp; or is a viral antigen of the hepatitis A, B or C virus, the influenza virus, the respiratory syncytial virus, the rhinovirus, the West Nile virus, the rabies virus, the poliovirus, the HIV virus, the dengue virus, the Japanese encephalitis virus, the yellow fever virus, the cytomegalovirus or the herpes virus; or is a parasitic antigen of Plasmodium sp., Leishmania sp. or Schistosoma sp.; or is a tumor antigen.
10. The vaccine composition of claim 7 , wherein the at least one vaccine agent is an antigen or a vector being originated from Staphylococcus aureus or from the cytomegalovirus.
11. The vaccine composition of claim 7 , which is capable of raising an immune response in an animal or human, with enhancement of the obtained Th1 immune response and/or with a balance between the obtained Th1 and Th2 immune responses.
12. The vaccine adjuvant of claim 4 , wherein the buffered aqueous solution has a pH in a range of 5.5 to 8.8.
13. The vaccine adjuvant of claim 1 , wherein the pharmaceutically acceptable salt of a linear or branched polyacrylic acid polymer is a 20-50 kDa cut-off diafiltered pharmaceutically acceptable salt of a linear or branched polyacrylic acid polymer.
14. The vaccine adjuvant of claim 1 , wherein the polyacrylic acid polymer salt comprises less than 0.001% w/w of oxidizing agents.
15. The vaccine adjuvant of claim 1 , wherein the oxidizing agent is a persulfate.
16. The vaccine adjuvant of claim 1 , wherein the polyacrylic acid polymer salt is a salt with Na +.